Emerging high-throughput drug target validation technologies.
Identifying the right target for drug development is a critical bottleneck in the pharmaceutical and biotech industries. The genomics revolution has shifted the problem from a scarcity of targets to a surplus of putative drug targets. As the validity of a target cannot be simply inferred from correlative data, the key is confirmation of the causative role of a gene product in a particular disease. It should therefore be recognized that an effective therapeutic strategy requires an appropriate target validation technology to verify the right target.
Ilag
Leodevico L
LL
Xerion Pharmaceuticals, Fraunhoferstr. 9, 82152 Martinsried, Germany. l.ilag@xerion-pharma.com
Ng
Jocelyn H
JH
Beste
Gerald
G
Henning
Stefan W
SW
D001709:Biotechnology / Q000639:trends; D004353:Drug Evaluation, Preclinical / Q000379:methods / Q000639:trends*; D004345:Drug Industry / Q000639:trends; D023281:Genomics; D010641:Phenotype; D011506:Proteins / Q000737:chemistry / Q000235:genetics; D015203:Reproducibility of Results; D012371:Robotics
D011506:Proteins